Skip to content
Menu
About Us
Company Overview
Management
Board of Directors
Our Science
Overview of Assets
Science
Pipeline
Clinical Trials
Expanded Access Policy
Newsroom
Press Releases
Events & Presentations
Investor Relations
Corporate Governance
Financial Information
Annual Reports & Proxy Statements
Investor Contact Info
Contact
Close Menu
Press Releases
December 18, 2023
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
View/download press release »
Sign up to receive press releases via email
Leave this field empty if you're human:
